OrthoPediatrics Stock Forecast, Price & News

+1.64 (+2.43 %)
(As of 09/23/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume41,586 shs
Average Volume139,234 shs
Market Capitalization$1.36 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive KIDS News and Ratings via Email

Sign-up to receive the latest news and ratings for OrthoPediatrics and its competitors with MarketBeat's FREE daily newsletter.

OrthoPediatrics logo

About OrthoPediatrics

OrthoPediatrics Corp. is a medical device company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. Its products includes PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, RESPONSE Spine, Bandloc and Pediguard. The company was founded by Erin Springer Yount and Nick A. Deeter in August 2006 and is headquartered in Warsaw, IN.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.30 out of 5 stars

Medical Sector

242nd out of 1,351 stocks

Surgical & Medical Instruments Industry

29th out of 123 stocks

Analyst Opinion: 1.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

OrthoPediatrics (NASDAQ:KIDS) Frequently Asked Questions

Is OrthoPediatrics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OrthoPediatrics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OrthoPediatrics stock.
View analyst ratings for OrthoPediatrics
or view top-rated stocks.

What stocks does MarketBeat like better than OrthoPediatrics?

Wall Street analysts have given OrthoPediatrics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OrthoPediatrics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is OrthoPediatrics' next earnings date?

OrthoPediatrics is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for OrthoPediatrics

How were OrthoPediatrics' earnings last quarter?

OrthoPediatrics Corp. (NASDAQ:KIDS) announced its quarterly earnings results on Wednesday, August, 4th. The company reported ($0.11) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.21) by $0.10. The business had revenue of $26.70 million for the quarter, compared to the consensus estimate of $24.14 million. OrthoPediatrics had a negative trailing twelve-month return on equity of 7.64% and a negative net margin of 36.61%.
View OrthoPediatrics' earnings history

How has OrthoPediatrics' stock price been impacted by Coronavirus (COVID-19)?

OrthoPediatrics' stock was trading at $39.75 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, KIDS shares have increased by 73.9% and is now trading at $69.14.
View which stocks have been most impacted by COVID-19

What guidance has OrthoPediatrics issued on next quarter's earnings?

OrthoPediatrics updated its FY 2021 earnings guidance on Wednesday, September, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $97 million-$101 million, compared to the consensus revenue estimate of $96.09 million.

What price target have analysts set for KIDS?

4 brokers have issued 12 month price objectives for OrthoPediatrics' shares. Their forecasts range from $57.00 to $80.00. On average, they anticipate OrthoPediatrics' stock price to reach $72.50 in the next year. This suggests a possible upside of 4.9% from the stock's current price.
View analysts' price targets for OrthoPediatrics
or view top-rated stocks among Wall Street analysts.

Who are OrthoPediatrics' key executives?

OrthoPediatrics' management team includes the following people:
  • David R. Bailey, President & Chief Executive Officer
  • Fred L. Hite, Director, Chief Operating & Financial Officer (LinkedIn Profile)
  • Peter F. Armstrong, Chief Medical Officer
  • Joel Batts, Senior Vice President-Science & Technology
  • Greg Odle, Executive Vice President

What is Mark Throdahl's approval rating as OrthoPediatrics' CEO?

15 employees have rated OrthoPediatrics CEO Mark Throdahl on Mark Throdahl has an approval rating of 100% among OrthoPediatrics' employees. This puts Mark Throdahl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of OrthoPediatrics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OrthoPediatrics investors own include AbbVie (ABBV), Freeport-McMoRan (FCX), Gilead Sciences (GILD), Intel (INTC), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Cisco Systems (CSCO), The Walt Disney (DIS), Enterprise Products Partners (EPD) and NVIDIA (NVDA).

When did OrthoPediatrics IPO?

(KIDS) raised $52 million in an IPO on Thursday, October 12th 2017. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Piper and Jaffray Stifel served as the underwriters for the IPO and William Blair and BTIG were co-managers.

What is OrthoPediatrics' stock symbol?

OrthoPediatrics trades on the NASDAQ under the ticker symbol "KIDS."

Who are OrthoPediatrics' major shareholders?

OrthoPediatrics' stock is owned by many different institutional and retail investors. Top institutional investors include Brown Capital Management LLC (13.83%), BlackRock Inc. (4.78%), Vanguard Group Inc. (3.71%), Next Century Growth Investors LLC (3.06%), Wasatch Advisors Inc. (2.89%) and DF Dent & Co. Inc. (2.37%). Company insiders that own OrthoPediatrics stock include (Reynolds) Marie C Infante, Bernie B Berry III, Bernie B Berry III, Daniel J Gerritzen, David R Bailey, David R Pelizzon, Fred Hite, Gregory A Odle, Jennifer N Pritzker, Mark C Throdahl, Stephen F Burns and Terry D Schlotterback.
View institutional ownership trends for OrthoPediatrics

Which institutional investors are selling OrthoPediatrics stock?

KIDS stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Millennium Management LLC, Next Century Growth Investors LLC, DF Dent & Co. Inc., BlackRock Inc., American Century Companies Inc., Squarepoint Ops LLC, and State Street Corp. Company insiders that have sold OrthoPediatrics company stock in the last year include (Reynolds) Marie C Infante, Bernie B Berry III, Daniel J Gerritzen, David R Bailey, Fred Hite, Gregory A Odle, Mark C Throdahl, Stephen F Burns, and Terry D Schlotterback.
View insider buying and selling activity for OrthoPediatrics
or view top insider-selling stocks.

Which institutional investors are buying OrthoPediatrics stock?

KIDS stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Brown Capital Management LLC, Lisanti Capital Growth LLC, M&G Investment Management Ltd., Morgan Stanley, Morgan Stanley, Amundi, and Point72 Asset Management L.P.. Company insiders that have bought OrthoPediatrics stock in the last two years include David R Pelizzon, and Jennifer N Pritzker.
View insider buying and selling activity for OrthoPediatrics
or or view top insider-buying stocks.

How do I buy shares of OrthoPediatrics?

Shares of KIDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OrthoPediatrics' stock price today?

One share of KIDS stock can currently be purchased for approximately $69.14.

How much money does OrthoPediatrics make?

OrthoPediatrics has a market capitalization of $1.36 billion and generates $71.08 million in revenue each year. The company earns $-32,940,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis.

How many employees does OrthoPediatrics have?

OrthoPediatrics employs 116 workers across the globe.

What is OrthoPediatrics' official website?

The official website for OrthoPediatrics is

Where are OrthoPediatrics' headquarters?

OrthoPediatrics is headquartered at 2850 Frontier Drive, Warsaw IN, 46582.

How can I contact OrthoPediatrics?

OrthoPediatrics' mailing address is 2850 Frontier Drive, Warsaw IN, 46582. The company can be reached via phone at (574) 268-6379 or via email at [email protected].

This page was last updated on 9/24/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.